Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients

Background Human T-lymphotropic virus type 1 (HTLV-1) infects an estimated 10 million persons globally with transmission resulting in lifelong infection. Disease, linked to high proviral load, occurs in a minority. In established infection HTLV-1 replicates through infectious spread and clonal expansion of infected lymphocytes. Little is known about acute HTLV-1 infection. The kinetics of early HTLV-1 infection, following transplantation-acquired infection in three recipients from one HTLV-1 infected donor, is reported. The recipients were treated with two HTLV-1 enzyme inhibitors 3 weeks post exposure following the detection of HTLV-1 provirus at low level in each recipient. HTLV-1 infection was serially monitored by serology, quantification of proviral load and HTLV-1 2LTR DNA circles and by HTLV-1 unique integration site analysis. Results HTLV-1 antibodies were first detected 16–39 days post-transplantation. HTLV-1 provirus was detected by PCR on day 16–23 and increased by 2–3 log by day 38–45 with a peak proviral doubling time of 1.4 days, after which steady state was reached. The rapid proviral load expansion was associated with high frequency of HTLV-1 2LTR DNA circles. The number of HTLV-1 unique integration sites was high compared with established HTLV-1 infection. Clonal expansion of infected cells was detected as early as day 37 with high initial oligoclonality index, consistent with early mitotic proliferation. Conclusions In recipients infected through organ transplantation HTLV-1 disseminated rapidly despite early anti-HTLV-1 treatment. Proviral load set point was reached within 6 weeks. Seroconversion was not delayed. Unique integration site analysis and HTLV-1 2LTR DNA circles indicated early clonal expansion and high rate of infectious spread.


Background
Human T-lymphotropic virus type-1 (HTLV-1) is associated with two main clinical disorders that arise in 5-8 % of carriers: HTLV-1 associated myelopathy (HAM), a progressive, inflammatory, spastic paraparesis, and adult T cell leukaemia/lymphoma (ATLL), an aggressive malignancy of CD4+ T-lymphocytes. The majority of infection occurs through sexual intercourse or from mother-to-child during breast feeding but infection from unscreened blood transfusions or organ transplants can occur [1]. Little is known about early HTLV-1 infection, which is asymptomatic, but data from recipients of infected blood transfusions suggest that most seroconversion occurs within 2 months [2]. Knowledge of the course of early HTLV-1 infection in immunosuppressed individuals is limited to case reports of HTLV-1-associated disease following infection at the time of organ transplantation with infection usually not recognised until the onset of symptoms [3][4][5][6][7][8][9][10][11][12].

Open Access
Retrovirology *Correspondence: l.cook@imperial.ac.uk Evidence from phylogenetic studies and integration site analysis reveals two routes by which HTLV-1 propagates within the host [13][14][15][16]: infectious spread, where the virus spreads from cell-to-cell through the formation of a virological synapse between infected and uninfected CD4+ T-cells [17], resulting in integration of the HTLV-1 provirus in a new genomic location in the newly infected host cell; and mitotic proliferation of infected CD4+ T-lymphocytes, which gives rise to clonal populations of infected CD4+ cells that can be identified and quantified by their unique genomic integration site [16].
The relative contributions of infectious and mitotic spread at different time points of infection are not known; this knowledge is required for designing rational treatment protocols. HTLV-1 viral RNA is rarely found in human plasma [21,22], which is not infectious [23]. In HIV infection, viral episomes containing two long terminal repeats (2LTR DNA circles) are formed after completion of viral cDNA synthesis and translocation of the viral genome to the host cell nucleus, where recombination and direct ligation lead to the formation of episomes. For HIV there is evidence that these 2LTR DNA circles are a surrogate marker of ongoing viral replication [18][19][20] in the absence of detectable viral RNA. HTLV-1 2LTR DNA circles have not been studied previously.
Since late 2002, all blood donations in the UK have been screened for HTLV-1 [24] but real-time screening of organ donors only became universal in 2012, after the events reported here. We report the investigation and management of three transplant recipients exposed to HTLV-1 through solid organ transplantation from a single donor, which leads to new insights into the early spread of HTLV-1 infection in vivo.

Results
Clinical cases (Table 1) The liver and both kidneys were retrieved from a deceased female Caucasian donor, who was not known to carry, and had no risk factors for, HTLV-1 infection. The organs were transplanted in accordance with UK Blood and Transplant service protocols to three HLA classmatched male recipients. At the time of organ retrieval the donor HTLV status was reported as 'awaited' but after transplantation the HTLV-1 seropositive status of the donor was detected and confirmed, following which the recipients were informed. No suitable samples for quantifying the proviral load of the donor were available. Clinical details of the recipients are summarised in Table 1. In one patient, the transplanted kidney was explanted within 12 h because of life-threatening haemorrhage (unconnected with the infection); the other kidney recipient developed allograft rejection and so underwent explantation. The liver recipient, treated with standard immunosuppression, remains well with normal graft function.

HTLV-1 long terminal repeat (LTR) sequence identity
Alignment of 442 nucleotides of the HTLV-1 5′LTR showed 100 % sequence identity between the three individuals, consistent with a common viral source of infection.

HTLV-1 proviral load and doubling time (Fig. 2)
At 16 days post-transplantation HTLV-1 provirus could not be detected by quantitative PCR (qPCR) in any of the recipients (<0.01 % PBMC infected). However, by nested PCR provirus was detectable and estimated at 0.003 % PBMC in Case 1 (liver transplant) and at 0.01 % in Case 2 (kidney transplant) but remained undetectable in Case 3 (kidney transplant) until day 23 when it became detectable Since it is known that there is a single copy of HTLV-1 integrated into each infected cell [28], the proviral load between the early time points can be used to estimate the doubling time of HTLV-1 infected CD4+ T-lymphocytes in the first month following infection which at its peak was a median of 1.43 days (range 1.1-2.9 days). The absolute lymphocyte count remained in the low normal range during this period (data not shown).

HTLV-1 2LTR DNA circles (Fig. 2)
In DNA circles/infected cell) followed by a second peak at day 142 (0.16 2LTR DNA circles/infected cell) coinciding with a peak in the proviral load.
In all three cases, longitudinal analysis shows that the frequency of 2LTR DNA circles peaked between days 31 and 38 post-transplant at the same time as the initial peak in proviral load and whilst the patients were taking HTLV-1 reverse transcriptase and integrase inhibitors. The reduction in frequency of 2LTR DNA circles thereafter was greater than the reduction in proviral load (Fig. 2).

Unique integration site (UIS) analysis (Fig. 3)
Each clone of infected cells can be defined by a unique genomic integration site [28]   At the earliest available time points HTLV-1 proviral load was too low to undertake high-throughput sequencing (HTS). HTS revealed that no integration site was found in more than one recipient, indicating that the observed integration sites were not persistent donor lymphocytes.
In Case 1 the degree of oligoclonal proliferation, measured by the oligoclonality index [16], peaked at day 59 and then plateaued, while the number of UIS slowly increased (Panel C). The absolute abundance of HTLV-1-infected clones was low compared with chronic infection acquired either from mother-to-child transmission or through sexual intercourse [16]. In both relative and absolute abundance clones present at day 61 were of lower abundance if redetected at day 186.
Case 2: At the first time point a large number of UIS (1031) were detected and the oligoclonality index was high; both these parameters subsequently decreased (Panel C). In this case the peak proviral load may be attributed to both an increase in the absolute number of integration sites (suggesting infectious spread) and vigorous expansion of a small number of clones.
Case 3: The oligoclonality index, reflecting clonal proliferation, peaked at day 48 and then declined over the next 3 months, with an increase in the absolute number of UIS consistent with infectious spread (Panel C).

Estimated number of clones
The number of clones was estimated from the integration site high throughput sequencing data using a newly developed and published method, DivE. DivE compares multiple mathematical models fitted to rarefaction curves, which give the expected number of infected clones as a function of the number of infected cells. The estimated number of clones (median 1.3 × 10 5 ) in these transplant recipients was substantially higher than those previously obtained in asymptomatic carriers (median 9.0 × 10 3 ) [28], patients with HAM (median 2.8 × 10 4 ) [29], and patients ATLL with (median 1.7 × 10 3 ) [30].

Discussion
For the majority of individuals, HTLV-1 is transmitted from mother-to-child via breast feeding and as such it is nearly impossible to conduct a study during acute infection. This report of an unfortunate clinical event has provided a rare opportunity to quantify the kinetics of acute HTLV-1 infection. We report that anti-HTLV-1 antibody responses were not delayed by immunosuppressive therapy: Anti-HTLV antibodies were detected in two cases at the first available time point (day 16) and in the third by day 39. This is similar to reports from recipients of HTLV-1-infected blood transfusions, in whom the seroconversion window has been estimated at 55 days [31], with 50 % having detectable HTLV-1 antibodies by day 40 [2], and contrasts with the recent report of delayed seroconversion in transplant recipients [4] .
We report that HTLV-1 spread early and rapidly in the three transplant recipients. In established HTLV-1 infection the proviral load varies more than 5 logs between individuals, and a high proviral load predicts and predates HTLV-1-associated disease. Proviral load remains stable within an individual over many years [32][33][34] but it has not been established how early this proviral load 'set-point' is reached. In the three recipients described here, who were immunosuppressed to different degrees, the 'set-point' proviral load was established by day 32-36 post-exposure after a rapid increase in proviral load with a median peak proviral doubling time of 1.4 days.
Early HTLV-1 spread is both 'infectious' and 'mitotic' . We observed that the HTLV-1 2LTR DNA circles peaked with the peak proviral load, and both declined by the next testing time point. 2LTR DNA circles have not been previously reported in HTLV-1 infection and thus there are no data on the survival of such episomal viral DNA in HTLV-1 infection. The assumption that these 2LTR DNA circles are markers of recent infection is based upon this phenomenon in HIV [18]. Here, we provide evidence in HTLV-1 infection that 2LTR DNA circles are detected, and that they, or the cells in which they exist, are relatively short lived being much less frequent, as a proportion of infected cells, 2 weeks after the peak. The peak of 2 LTR DNA circles was observed after the introduction of oral antiretroviral therapy and there are two explanations for this: Firstly, whilst raltegravir has been demonstrated to prevent HTLV-1 spread from infected to uninfected cells in vitro [27], the therapy may not be active in vivo, even in primary infection due to reduced viral susceptibility. Secondly, early infectious spread may have already occurred, prior to the introduction of antiretroviral therapy, in a reservoir of inaccessible lymphoid tissue with later 'spill over' into the peripheral blood.
In each case, the peak oligoclonality index also coincided with the peak proviral load. The oligoclonality index reflects the degree of mitotic proliferation, which in case 2 at day 39 (Fig. 3, panel A) scored >0.8, in the range normally observed in ATLL. In each case, the oligoclonality index then decreased and stabilised in the range observed in chronic asymptomatic infection (0.3-0.55). The peak in the oligoclonality index also coincided with the peak frequency of 2LTR DNA circles. These results demonstrate both the expected early infectious spread and unexpected profound early mitotic proliferation which subsequently diminished.
It is unclear whether the therapeutic immune suppression during transplantation allowed rapid expansion of particular clones, which subsequently reduced in both absolute and relative abundance, or whether the period of antiretroviral therapy altered the balance between infectious spread and mitotic proliferation. Antiretroviral therapy was delivered by day 23 post-transplantation at therapeutically relevant doses but appeared unable to inhibit the early infectious spread of HTLV-1. In both in vitro [35,36] and in vivo studies [25], zidovudine has previously been shown to effectively inhibit HTLV-1 infection. Similarly, raltegravir has also shown effectiveness in vitro [27]. The usefulness of these drugs in humans in early infection has never before been tested but these aforementioned studies provided the rational for their use here. It is possible that the effectiveness of these drugs in vitro and in animal models does not translate to humans or, as we believe more likely, that drug treatment was initiated after its potential therapeutic window.
In this setting, treatment with zidovudine and raltegravir did not control early infectious spread of HTLV-1. Since donor infection was diagnosed too late for post-exposure prophylaxis, antiretroviral therapy was initiated with the intention of limiting infectious spread during the most intense phase of immune suppression. The data suggest that the treatment started between day 16 and day 23 post-infection had no impact upon infectious spread and therefore once HTLV-1 proviral loads exceeded 1 % this treatment was discontinued. However, these results do not exclude a possible benefit of earlier post or peri-exposure prophylaxis.
Early onset and rapid progression of HAM, as previously reported [5,6] was not observed. Further data are required on the long-term outcome of recipients of HTLV-1-infected organ transplants because in the context of an urgent life-saving transplant, such as liver or heart, the balance of risk and benefit may favour transplantation, even from a HTLV-1 infected donor.

Conclusions
Following transplant-acquired infection: serological and molecular evidence of HTLV-1 can be detected as early as Day 16; the proviral set point is reached within 6 weeks and is the consequence of both mitotic and infectious spread; and there is no evidence that HTLV-1 enzyme inhibitors given from Day 16 of infection impact on the final proviral load.

Methods
Relevant clinical details were abstracted from the medical records of each patient. In each case 8-11 sequential blood samples were obtained from day 16 until 21 months post-transplantation.

Antibody detection
HTLV-1 antibodies were detected by Murex HTLV I + II (Diasorin Ltd, Dartford, UK) and confirmed by Western blot using Genelabs Diagnostics ® HTLV 2.4 assay (Genelabs, Redwood City, CA, USA) according to the manufacturer's protocols.

HTLV-1 proviral load
HTLV-1 proviral load was quantified by quantitative PCR (qPCR) as previously reported [32] with primers to the proviral tax and human β-globin gene, assuming one copy of tax [23] and two copies of β-globin per infected cell. Samples with unquantifiable provirus by qPCR (proviral load <0.01 % PBMCs) were amplified by nested PCR (nPCR) to confirm presence of provirus. The peak doubling time (T2) for proviral HTLV-1 was estimated from the sequential data as follows and a median result calculated: where V1 and V2 are the proviral loads at the first and second time-points, respectively and T is the time between measurements.

Clonal abundance of Integration sites by high throughput sequencing (HTS)
A customised HTS protocol to map and accurately quantify proviral integration sites was used as previously described [16]. Fifty base-pair paired-end reads were acquired on an Illumina HiSeq 2000 analyser and the relative and absolute abundance of each clone deduced.

Estimation of oligoclonality index (OCI)
As previously described, the OCI calculates the dispersion of a clonal population, describing the contribution of the largest clones to the total proviral load. An OCI close to 0 suggests a polyclonal population, where each clone occupies an equal share of the proviral load, whilst an OCI close to 1 suggests a dominant single clone [16].

Diversity estimator (DivE)
DivE fits multiple mathematical models to nested subsamples of rarefaction curves, which depict the number of HTLV-1 infected clones against the number of HTLV-1 infected cells. Model performance is assessed by measuring the extent to which full data can be estimated from subsamples. Clonal diversity is estimated by extrapolating the best-performing models to a given population size (here the number of HTLV-1 infected cells in the circulation) [29]. A PBMC count of 3 × 10 9 /L was assumed in estimating the number of HTLV-1 infected cells.

Ethics statement
The organs of the donor were offered for transplantation by the family of the donor, with written consent by the next-of-kin in accordance with the Human Tissues Act 2004 and the regulations of the Human Tissues Authority. In the United Kingdom this donation process and consent includes the testing of the donor for transplantation transmissible infections including HTLV-1. Each recipient gave written informed consent for the organ transplantation which is documented in the medical records. In the UK verbal consent alone is sufficient to obtain blood samples for clinical purposes and this is not separately documented. Although some new investigation techniques were applied in the clinical investigation of this unusual event these were not performed as part of a research study and therefore in accordance with the guidance of the relevant authority, which in England is the Health Research Authority, application to the National Research Ethics Service is not required. Furthermore, each recipient gave their consent for the HTLV investigations and separately and specifically each gave consent, documented in their medical records, for the publication of their case and the results of their investigations.